Inclusion Criteria: - Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive. - Women not of childbearing potential (must have documented proof). - Males who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with BMS-986177 for a total of 92 days after completion of study treatment. Male participants must additionally refrain from sperm donation during this time. Exclusion Criteria: - Women of childbearing potential or who are breastfeeding. - Any significant acute or chronic medical illness, including tinnitus or any other condition listed as a contraindication in the aspirin package insert. - History of dizziness and/or recurrent headaches (i.e. daily headaches lasting for 1 week's duration in the last month prior to study treatment administration). - History of head injury in the last 2 years, including participants with base skull fractures, intracranial tumor, or aneurysm. - History of gastroesophageal reflux disease, dyspepsia (indigestion), protracted nausea, or chronic diarrhea (defined as 3 or 4 loose stools per day that last for ≥ 4 weeks) within the past 6 months. - Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study. - Use of tobacco- or nicotine-containing products (including, but not limited to, cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 6 months prior to study treatment administration. - History of any adverse reaction to anticoagulants or antiplatelet agents that resulted in excessive bleeding, requiring medication intervention. Other protocol-defined inclusion/exclusion criteria could apply.